pentoxifylline has been researched along with Cardiovascular Stroke in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 9.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 8.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "We have observed that, after myocardial infarction (MI), rats display apoptosis in the limbic system that can be prevented by pentoxifylline (PTX), a proinflammatory cytokine inhibitor." | 7.77 | Pretreatment with pentoxifylline has antidepressant-like effects in a rat model of acute myocardial infarction. ( Bah, TM; Godbout, R; Kaloustian, S; Rousseau, G, 2011) |
| " The effect of the haemorrheological agent pentoxifylline was investigated in a canine model of acute myocardial infarction, induced by occlusion of the left anterior descending coronary for 6 h." | 7.67 | Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction. ( Campbell, CA; Clavenna, CF; Kloner, RA; Wynne, J, 1988) |
| "Pentoxifylline is a methylxanthine derivative with known anti-inflammatory, antioxidant, vasodilator, and rheological properties which can be a promising agent in preventing reperfusion injury." | 7.30 | Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI). ( Aghakouchakzadeh, M; Amoli, AI; Hosseini, SH; Jalali, A; Jenab, Y; Kakavand, H; Naderian, M; Pourhosseini, H; Saadatagah, S; Sadri, F; Salarifar, M; Talasaz, AH, 2023) |
| "Pentoxifylline has more beneficial potencies in reducing adverse events after coronary artery bypass graft using cardiopulmonary bypass, than what are known." | 6.80 | Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). ( Abbasi, K; Bina, P; Boroumand, MA; Fehri, A; Karimi, AA; Mansourian, S, 2015) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 5.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 4.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| " We hypothesized that inhibition of neuroinflammation by the PIC synthesis inhibitor, pentoxifylline (PTX) would prevent depression-like behaviors induced by heart failure (HF) post-MI in OVX female rats." | 3.91 | Role of Myocardial Infarction-Induced Neuroinflammation for Depression-Like Behavior and Heart Failure in Ovariectomized Female Rats. ( Ahmad, M; Lagace, D; Leenen, FHH; Najjar, F, 2019) |
| "We have observed that, after myocardial infarction (MI), rats display apoptosis in the limbic system that can be prevented by pentoxifylline (PTX), a proinflammatory cytokine inhibitor." | 3.77 | Pretreatment with pentoxifylline has antidepressant-like effects in a rat model of acute myocardial infarction. ( Bah, TM; Godbout, R; Kaloustian, S; Rousseau, G, 2011) |
| " The effect of the haemorrheological agent pentoxifylline was investigated in a canine model of acute myocardial infarction, induced by occlusion of the left anterior descending coronary for 6 h." | 3.67 | Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction. ( Campbell, CA; Clavenna, CF; Kloner, RA; Wynne, J, 1988) |
| "Pentoxifylline is a methylxanthine derivative with known anti-inflammatory, antioxidant, vasodilator, and rheological properties which can be a promising agent in preventing reperfusion injury." | 3.30 | Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI). ( Aghakouchakzadeh, M; Amoli, AI; Hosseini, SH; Jalali, A; Jenab, Y; Kakavand, H; Naderian, M; Pourhosseini, H; Saadatagah, S; Sadri, F; Salarifar, M; Talasaz, AH, 2023) |
| "Pentoxifylline has more beneficial potencies in reducing adverse events after coronary artery bypass graft using cardiopulmonary bypass, than what are known." | 2.80 | Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). ( Abbasi, K; Bina, P; Boroumand, MA; Fehri, A; Karimi, AA; Mansourian, S, 2015) |
| "Myocardial infarction was produced in anesthetized rats by a 40-minute occlusion of the left anterior descending coronary artery followed by 72 hours of reperfusion." | 1.33 | Apoptosis detected in the amygdala following myocardial infarction in the rat. ( Boucher, M; Godbout, R; Kaloustian, S; Nim, S; Rousseau, G; Wann, BP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Kakavand, H | 1 |
| Saadatagah, S | 1 |
| Naderian, M | 1 |
| Aghakouchakzadeh, M | 1 |
| Jalali, A | 1 |
| Sadri, F | 1 |
| Amoli, AI | 1 |
| Hosseini, SH | 1 |
| Jenab, Y | 1 |
| Pourhosseini, H | 1 |
| Salarifar, M | 1 |
| Talasaz, AH | 1 |
| Elseweidy, MM | 1 |
| Ali, SI | 1 |
| Shaheen, MA | 1 |
| Abdelghafour, AM | 1 |
| Hammad, SK | 1 |
| Brown, T | 1 |
| Forster, RB | 1 |
| Cleanthis, M | 2 |
| Mikhailidis, DP | 2 |
| Stansby, G | 2 |
| Stewart, M | 2 |
| Namdar, H | 1 |
| Zohori, R | 1 |
| Aslanabadi, N | 2 |
| Entezari-Maleki, T | 2 |
| Najjar, F | 1 |
| Ahmad, M | 1 |
| Lagace, D | 1 |
| Leenen, FHH | 1 |
| Bedenis, R | 1 |
| Robless, P | 1 |
| Shirzadi, HR | 1 |
| Asghari-Soufi, H | 1 |
| Dousti, S | 1 |
| Ghaffari, S | 1 |
| Sohrabi, B | 1 |
| Mashayekhi, SO | 1 |
| Hamishehkar, H | 1 |
| Mansourian, S | 1 |
| Bina, P | 1 |
| Fehri, A | 1 |
| Karimi, AA | 1 |
| Boroumand, MA | 1 |
| Abbasi, K | 1 |
| Bah, TM | 1 |
| Kaloustian, S | 2 |
| Rousseau, G | 2 |
| Godbout, R | 2 |
| Francis, J | 1 |
| Chu, Y | 1 |
| Johnson, AK | 1 |
| Weiss, RM | 1 |
| Felder, RB | 1 |
| Wann, BP | 1 |
| Boucher, M | 1 |
| Nim, S | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Lechleitner, P | 1 |
| Genser, N | 1 |
| Mair, J | 1 |
| Maier, J | 1 |
| Herold, M | 1 |
| Beimpold, H | 1 |
| Föger, B | 1 |
| Dienstl, F | 1 |
| Puschendorf, B | 1 |
| Tilg, H | 1 |
| Breddin, HK | 1 |
| Manrique, RV | 1 |
| Manrique, V | 1 |
| Campbell, CA | 1 |
| Clavenna, CF | 1 |
| Wynne, J | 1 |
| Kloner, RA | 1 |
| Badalian, GO | 1 |
| Episkoposian, NG | 1 |
| Amatuni, GV | 1 |
4 reviews available for pentoxifylline and Cardiovascular Stroke
| Article | Year |
|---|---|
Cilostazol for intermittent claudication.
Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pento | 2021 |
Cilostazol for intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifyll | 2014 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
6 trials available for pentoxifylline and Cardiovascular Stroke
| Article | Year |
|---|---|
Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI).
Topics: Administration, Intravenous; Antioxidants; Humans; Infusions, Intravenous; Myocardial Infarction; Pe | 2023 |
Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial.
Topics: Aged; Biomarkers; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Pen | 2017 |
A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention.
Topics: Aged; Creatine Kinase, MB Form; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Myo | 2015 |
Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%).
Topics: Administration, Oral; Aged; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial In | 2015 |
Pentoxifylline influences acute-phase response in acute myocardial infarction.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Female; Humans; Male; Midd | 1992 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
8 other studies available for pentoxifylline and Cardiovascular Stroke
| Article | Year |
|---|---|
Vanillin and pentoxifylline ameliorate isoproterenol-induced myocardial injury in rats
Topics: Animals; Inflammation; Isoproterenol; Myocardial Infarction; Myocardium; Oxidative Stress; Pentoxify | 2023 |
Role of Myocardial Infarction-Induced Neuroinflammation for Depression-Like Behavior and Heart Failure in Ovariectomized Female Rats.
Topics: Animals; Behavior Rating Scale; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Disease Mo | 2019 |
Pretreatment with pentoxifylline has antidepressant-like effects in a rat model of acute myocardial infarction.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Choice Behavior; Depressive Disorder; Disease Mode | 2011 |
Acute myocardial infarction induces hypothalamic cytokine synthesis.
Topics: Animals; Gene Expression; Heart Failure; Hypothalamo-Hypophyseal System; Male; Myocardial Infarction | 2004 |
Apoptosis detected in the amygdala following myocardial infarction in the rat.
Topics: Amygdala; Animals; Apoptosis; Cerebellum; Cytokines; Depressive Disorder, Major; Disease Models, Ani | 2006 |
Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Blood Platelets; Cyclic AMP; Drug Resist | 1987 |
Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction.
Topics: Animals; Blood Pressure; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; Heart Rat | 1988 |
[Effect of fructose-1,6-diphosphate and trental on the erythrocyte aggregating capacity in ischemic heart disease].
Topics: Adult; Aged; Alcian Blue; Angina Pectoris; Coronary Disease; Dose-Response Relationship, Drug; Drug | 1987 |